| 영문 | platelet | 한글 | 혈소판 |
|---|---|---|---|
| 설명 | 골수의 거대 세포인 거대핵세포의 세포질 일부가 떨어져서 순환 혈액 중에 출현한 것으로 직경이 2~4μm의 작은 과립체이다. 혈소판은 손상을 입은 혈관의 노출된 결합 조직에 붙어 여러 물질을 분비하여 지혈 및 혈액 응고에 중요한 역할을 한다. |
||
| 영문 | acquired immunodeficiency syndrome | 한글 | 후천면역결핍증후군, 에이즈 |
|---|---|---|---|
| 설명 | 인간면역결핍바이러스(HIV)에 의하여 면역 세포가 파괴됨으로써 인체의 면역능력이 극도로 저하되어 병원체에 대하여 무방비 상태에 이르는 병. 에이즈 바이러스의 감염으로 생기며, 1981년 미국에서 처음 보고되었다. 최초 감염으로부터 증상이 나타나기까지는 평균 10년 정도 걸리며 사망률이 대단히 높다. 성적 접촉, 오염 주사기 사용, 오염 혈액 및 혈액 제제 사용, 에이즈 산모로부터 수직감염 따위에 의하여 감염된다. 감염 후 일과성으로 감기와 같은 증상을 보이며 바이러스혈증으로 되지만 바이러스는 감소되고 6~8주 후에는 항체가 양성으로 된다. 6~10년 정도의 무증후성 보균기간을 지나서 에이즈관련증후군(AIDS related syndrome)으로 된다. 저항력의 감소, 림프절비대, 체중감소, 발열, 만성설사가 이어진다. 그 후 에이즈로 되며, 폐포자충폐렴 등의 원충병, 칸디다 등의 진균증, 헤르페스바이러스군 등의 기회감염이 이어진다. 또한 카포시육종, 림프종 등을 병발해서 사망한다. 바이러스의 뇌조직내 증식으로 치매를 일으킬 수도 있다. HIV-1은 10년간에 사망률이 90%, HIV-2는 10%이다. |
||
| 영문 | liver function tests | 한글 | 간기능검사 |
|---|---|---|---|
| 설명 | 혈액검사중 가장 많이 쓰이는 검사법으로 다음 7가지를 검사하게 된다. 혈청콜레스테롤, 총단백질, 알부민, 빌리루빈, GOT/GPT 효소, 알칼리인산분해효소(alkaline phophatase) 등을 검사하게 되는 데 각 검사치에는 모두 의미가 있으며, 이 검사 하나로 간기능의 전반적인 상태에 대해서 알아볼 수 있다. |
||
| 영문 | pulmonary function tests | 한글 | 폐기능 검사 |
|---|---|---|---|
| 설명 | 여러 가지 기구를 이용해 폐용적 및 허파의 확산능을 알아보는 검사로 말 그대로 허파의 기능을 측정하는 검사이다. |
||
| PULSES | physical condition, upper limb function, lower limb function, sensory component, excretory function,... |
|---|---|
| PFT | 1) Platelet Function Test 2) Pulmonary Function Test |
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| ASD | aldosterone secretion defect; Alzheimer senile dementia; antisiphon device; arthritis syphilitica de... |
| IASD | interatrial septal defect; inter-auricular septal defect |
| ASD | Atrial septal defect |
|---|---|
| CHD | Congenital heart defect |
| CSD | critical size defect |
| LPD | Luteal phase defect |
| MD | Mean Defect |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
|---|
| platelet function disorders | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (31 Dec 1997) |
|---|---|
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| platelet actomyosin | The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function. Synonym: thrombosthenin. (05 Mar 2000) |
| platelet adhesiveness | The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces. (12 Dec 1998) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
| platelet basic protein | <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin. (18 Nov 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|